DrugPatentWatch Database Preview
Bayer Healthcare Company Profile
What is the competitive landscape for BAYER HEALTHCARE, and when can generic versions of BAYER HEALTHCARE drugs launch?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are thirteen US patents protecting BAYER HEALTHCARE drugs.
There are two hundred and thirty-seven patent family members on BAYER HEALTHCARE drugs in fifty-three countries and six supplementary protection certificates in three countries.
Summary for Bayer Healthcare
| International Patents: | 237 |
| US Patents: | 13 |
| Tradenames: | 23 |
| Ingredients: | 13 |
| NDAs: | 29 |
| Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 021993-001 | Dec 12, 2006 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare Llc | ZEGERID OTC | omeprazole; sodium bicarbonate | CAPSULE;ORAL | 022281-001 | Dec 1, 2009 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,137,127 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Bayer Healthcare Llc | CLARITIN | loratadine | TABLET, CHEWABLE;ORAL | 021891-002 | Nov 21, 2018 | OTC | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare Llc | ZEGERID OTC | omeprazole; sodium bicarbonate | FOR SUSPENSION;ORAL | 022283-001 | Jun 17, 2013 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
Paragraph IV (Patent) Challenges for BAYER HEALTHCARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg/1100 mg | ➤ Subscribe | 2010-04-20 |
International Patents for Bayer Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2042504 | ➤ Sign Up |
| Hong Kong | 1195907 | ➤ Sign Up |
| Taiwan | I327570 | ➤ Sign Up |
| Brazil | 112017010141 | ➤ Sign Up |
| Japan | 6105008 | ➤ Sign Up |
| Costa Rica | 20130511 | ➤ Sign Up |
| Cyprus | 1109790 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1411900 | SPC/GB11/015 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 0152897 | 2001C/013 | Belgium | ➤ Sign Up | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
| 0984957 | SPC/GB11/013 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 1110543 | SPC/GB08/005 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| 0152897 | SPC/GB01/012 | United Kingdom | ➤ Sign Up | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
| 1110543 | 08C0004 | France | ➤ Sign Up | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
